Copy
Closer to a universal flu vaccine
View this email in your browser
Friends,  
Pasteur said "Chance favors the prepared mind." In that spirit, we continue preparing our collaboration with the NIH for their Phase 2 trial with our universal flu vaccine. We're also looking forward to results from our Phase 2b in Europe.
Please keep reading for more recent news. As always, we welcome your feedback.
I hope you're having a wonderful summer!
 - Ron Babecoff, President and CEO
Recent Highlights
> At BIO2016's panel Solving the Flu Problem: Can New Technologies Lead to Universal Flu Vaccines? Ron presented BiondVax's answer (Spoiler: yes!)
> BiondVax's year end and Q1 2016 results announced. We continue to meet milestones and stay on target. 
BIO2016 Flu Vaccine Panel 
Left to right: Jerry Sadoff (Janssen), Dan Stinchcomb (Flugen), Ron Babecoff (BiondVax), Armen Donabedian (BARDA)
August 3: Our CSO Tamar Ben-Yedidia discusses our ultimate vision: Flu eradication
Key Info

NASDAQ: BVXV

TASE: BVXV

 

Clinical Trials

5 completed
2 phase 2 trials ongoing in EU and USA

BiondVax is developing a universal flu vaccine to provide broadened and enhanced multi-season protection against seasonal and pandemic flu virus strains.
Biondvax universal flu vaccine M-001
Our vaccine utilizes a combination of conserved and common peptides from flu virus proteins, activating both arms of the immune system for broad coverage and long-lasting immunity.
Flu News
Another compelling justification for BiondVax's universal flu vaccine: Mounting evidence indicates the tropics experience unique annual flu patterns including multiple peaks, and mixed north and south strains. [Hirve et al, Plos]

Follow us:

Facebook
Twitter
LinkedIn
Google Plus
Copyright © 2016 BiondVax Pharmaceuticals Ltd., All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

Certain statements contained in this email, and in content linked to from this email, are forward-looking statements which involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of BiondVax Pharmaceuticals Ltd. ("the Company"), or industry results, to be materially different from any results performance or achievement expressed or implied by such forward-looking statements. Please refer to the Company’s filing with the Security and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in such forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements.



Email Marketing Powered by MailChimp